Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Attal

Showing results (111-120 of 153) with videos related to

Pageof 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Blood|September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's diseaseM André, M Henry-Amar, D Blaise, et al.
British Journal of Haematology|July 23, 1998
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsP Moreau, V Leblond, P Bourquelot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de MoelleD Blaise, M Kuentz, C Fortanier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2011
Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)E Jantunen, C Canals, M Attal, et al.
European Cytokine Network|March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remissionD Blaise, M Attal, J Reiffers, et al.
Bone Marrow Transplantation|November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)M Mohty, M Attal, G Marit, et al.
Leukemia & Lymphoma|November 9, 2001
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study GroupE Jourdan, J Reiffers, A M Stoppa, et al.
Bone Marrow Transplantation|January 15, 2014
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationF Baron, M Labopin, D Blaise, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Pageof 16

Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Blood|September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's diseaseM André, M Henry-Amar, D Blaise, et al.
British Journal of Haematology|July 23, 1998
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsP Moreau, V Leblond, P Bourquelot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de MoelleD Blaise, M Kuentz, C Fortanier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2011
Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)E Jantunen, C Canals, M Attal, et al.
European Cytokine Network|March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remissionD Blaise, M Attal, J Reiffers, et al.
Bone Marrow Transplantation|November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)M Mohty, M Attal, G Marit, et al.
Leukemia & Lymphoma|November 9, 2001
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study GroupE Jourdan, J Reiffers, A M Stoppa, et al.
Bone Marrow Transplantation|January 15, 2014
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationF Baron, M Labopin, D Blaise, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Pageof 16